Other Clinical Trial - The SurgiMend PRS Retrospective Study

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05736848` - A Retrospective Assessment of OviTex PRS (OviTex)
Recruiting	`NCT03171558` - Gastric Pull up Versus Free Flap Reconstruction for Laryngo-pharyngeal Defects	N/A
Completed	`NCT00633503` - Monitoring of Tissue Transfer Flaps by Modulated Imaging (MI) Spectroscopy
Recruiting	`NCT04115995` - DIEP Flap Perfusion Evaluated by DIRT and ICG-FA.

See also

Status

Clinical Trial

Phase

Recruiting

NCT05736848 - A Retrospective Assessment of OviTex PRS (OviTex)

Recruiting

NCT03171558 - Gastric Pull up Versus Free Flap Reconstruction for Laryngo-pharyngeal Defects

N/A

Completed

NCT00633503 - Monitoring of Tissue Transfer Flaps by Modulated Imaging (MI) Spectroscopy

Recruiting

NCT04115995 - DIEP Flap Perfusion Evaluated by DIRT and ICG-FA.

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05182177
Study type	Observational
Source	Integra LifeSciences Corporation
Contact	Andrew Tummon
Phone	609-529-5899
Email	andrew.tummon@integralife.com
Status	Recruiting
Phase
Start date	January 31, 2022
Completion date	December 31, 2024

The SurgiMend PRS Retrospective Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms